Meeder Asset Management’s Vir Biotechnology VIR Stock Holding History

Meeder Asset Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,885	Closed	-$137K	–	610
2023 Q1	$137K	Hold	5,885	–	–	0.01%	378
2022 Q4	$149K	Buy	5,885 +4,184	+246%	+$103K	0.01%	442
2022 Q3	$33K	Buy	1,701 +1,607	+1,710%	+$40.9K	﹤0.01%	955
2022 Q2	$2K	Buy	+94	New	+$2.19K	﹤0.01%	1930
2020 Q4	–	Sell	-560	Closed	-$19K	–	2236
2020 Q3	$19K	Buy	560 +438	+359%	+$18.9K	﹤0.01%	1190
2020 Q2	$5K	Buy	+122	New	+$4.09K	﹤0.01%	1539

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Meeder Asset Management's VIR Position: Q2 2023 in Review

Meeder Asset Management sold out of Vir Biotechnology (VIR) in Q2 2023, closing a stake of 5,885 shares — an estimated $137K sold.

Meeder Asset Management first reported a position in VIR in Q2 2020 and held it in 6 quarters. The position peaked at $149K in Q4 2022. 226 funds tracked by Wall St. Rank hold VIR as of Q2 2023.

Meeder Asset Management reported no remaining Vir Biotechnology position as of Q2 2023 after selling out during the quarter.
Meeder Asset Management sold 5,885 Vir Biotechnology shares in Q2 2023, an estimated $137K.
Meeder Asset Management first reported a position in Vir Biotechnology in Q2 2020 and held it in 6 quarters.
Meeder Asset Management's Vir Biotechnology position peaked at $149K in Q4 2022.
226 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2023.

Based on Meeder Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.